Clinical Trial Update: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on Ozanimod (RPC1063) in relapsing multiple sclerosis reports results from Phase 2 and Phase 3 efficacy and safety analysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ozanimod (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Relapsing Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-02-11